Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

VIRUS GENES is an esteemed journal published by Springer, dedicated to advancing our understanding of virology and its related fields, including genetics, molecular biology, and immunology. With a publication history that spans from 1987 to 2024, this journal provides researchers and professionals with a platform to disseminate high-quality, peer-reviewed articles that explore the intricacies of viral genetics and their implications in health and disease. With an impact factor placing it in the Q3 quartile across multiple categories in 2023, including Genetics and Virology, VIRUS GENES serves as a crucial resource for academics seeking to stay at the forefront of viral research. Its commitment to showcasing innovative research makes it an invaluable asset for students and professionals aiming to deepen their knowledge in the rapidly evolving landscape of virology. Although currently not offering Open Access, the journal ensures wide accessibility through institutional subscriptions, thereby playing a vital role in the collaboration between scientists globally.

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

Viruses-Basel, published by MDPI, is a leading interdisciplinary journal focused on the field of virology and infectious diseases, offering a platform for the rapid dissemination of high-quality research. Established in 2009, this open access journal has become an essential resource for researchers and health professionals, ensuring that critical findings are readily available to a global audience. With an impressive Q1 ranking in Infectious Diseases and a Q2 ranking in Virology as of 2023, the journal reflects its commitment to impactful research, validated by its notable positions within Scopus categories—ranked #84 out of 344 in Medicine: Infectious Diseases and #27 out of 80 in Immunology and Microbiology: Virology. The journal adheres to high standards of academic rigor, and by embracing an open access model, it promotes unrestricted access to scientific knowledge, fostering collaboration among researchers, professionals, and students alike. Situated in Basel, Switzerland, the journal serves as a cornerstone in the dissemination of research findings related to viral diseases and their implications on public health.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

The JOURNAL OF GENERAL VIROLOGY, published by the Microbiology Society, is a premier academic journal dedicated to advancing the field of virology. Established in 1967, this influential journal covers a wide spectrum of research from basic virology to applied studies, serving as a vital resource for researchers, professionals, and students alike. With its ISSN 0022-1317 and E-ISSN 1465-2099, the journal is recognized for its rigorous peer-review process and high-quality publications, attaining a commendable Q2 ranking in the Virology category for 2023. The journal's focus on disseminating innovative findings and fostering critical discussions contributes significantly to the understanding of viral mechanisms, disease processes, and potential therapeutic strategies. Although it does not currently offer Open Access options, the journal remains accessible to the academic community, with a strong commitment to supporting virology research globally. As part of Scopus' top-tier rankings, illustrating its impact within the category of Immunology and Microbiology, the JOURNAL OF GENERAL VIROLOGY continues to play a pivotal role in shaping the future of virological science.

Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

VIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.